CHIR98014, 10 mg

Stem cell researchers use this potent small-molecule glycogen synthase kinase-3 (GSK-3) inhibitor from STEMCELL Technologies to modulate Wnt/β-catenin signaling in human embryonic stem cell (hESC) and induced pluripotent stem cell (iPSC) cultures. CHIR98014 is supplied as 10 mg of lyophilized powder in a single-use vial and is intended for in vitro research use only.

Because the compound selectively inhibits GSK-3α and GSK-3β, it stabilizes β-catenin and supports long-term maintenance of pluripotency in feeder-free and defined-medium workflows. It is commonly deployed alongside MEK inhibitors in naive-state priming or resetting protocols, and it is incorporated into directed differentiation strategies that drive mesoderm, cardiac, and neural lineage outcomes. Published working concentrations generally fall within the 0.5 to 3 μM range, with titration recommended for each new cell line and medium formulation.

For stock preparation, dissolve in dimethyl sulfoxide (DMSO), aliquot to limit freeze-thaw cycles, and store at -20 °C protected from light. The 10 mg pack size supports multiple experimental campaigns spanning maintenance, reprogramming, and differentiation studies.